Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Neuroprotection Impact of Cyclosporin A in Cerebral Infarction (CsAStroke)

This study has been completed.
Information provided by (Responsible Party):
Hospices Civils de Lyon Identifier:
First received: January 31, 2012
Last updated: May 15, 2014
Last verified: January 2012

The main objective of this study is to determine whether a single injection of CsA after intravenous thrombolysis can significantly decreased the volume of cerebral infarction at day 30 ± 15 assessed with Flair MRI.

Secondary objectives are to determine whether a single injection of CsA after intravenous thrombolysis is safe and effective regarding to death and disability.

Condition Intervention Phase
Drug: Ciclosprin A
Drug: Injectable Saline Solution.
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Cyclosporin A Combined to Intravenous Thrombolysis. Multicenter Randomized Placebo-controlled

Resource links provided by NLM:

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • to determine whether a single injection of CsA after intravenous thrombolysis significantly decreased the volume of cerebral infarction at day 30 ± 15 in the T2-weighted Flair MRI. [ Time Frame: at day 30 ± 15 in the T2-weighted Flair MRI. ]
    Volume of cerebral infarction at day 30 ± 15 in the T2-weighted MRI Flair will be measured by manuel contouring by two independent radiologists uninformed of clinical and therapeutic data and therapeutic

Secondary Outcome Measures:
  • to determine whether a single injection of CsA after intravenous thrombolysis, is well tolerated and reduces deaths and disability in patients. [ Time Frame: on day 1, J7, J30, J90 ]
    Secondary endpoints include clinical scores: NIHSS , mRS, Death, SAE (within neurological worsening of more than 4 points on the NIHSS).

Enrollment: 126
Study Start Date: October 2009
Study Completion Date: December 2013
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ciclosporin A
Injection of 50 mg / ml IV infusion. 5 ml ampoules (250 mg of ciclosporin)
Drug: Ciclosprin A
The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
Placebo Comparator: Placebo
Injectable Saline Solution.
Drug: Injectable Saline Solution.
Saline Solution is administered once 15 min after thrombolysis.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients age ≥ 18 years and <85 years
  • Male or female,
  • Patients with cerebral infarction of less than 4:30H,
  • NIHSS score between 6 and 18
  • Identification of a carotid artery occlusion in the territory in MRI
  • Consent of participation signed by the patient or, if it is unable to give the family or someone you trust if it is present.
  • Patient beneficiary of a social security system.

Exclusion Criteria:

  • Known hypersensitivity to cyclosporin A or castor oil, polyoxyethylene
  • Patient in St. John's wort, stiripentol, bosentan or rosuvastatin
  • History of immunosuppression recent (<6 months): cancer, lymphoma, positive serology for HIV, hepatitis, ...
  • Known hepatic (prothrombin time <50%)
  • Patients treated with sulfonylureas or nicorandil
  • Patients treated with dopamine, adrenaline, noradrenaline or isoprenalin
  • Uncontrolled hypertension defined as systolic blood pressure greater than 185mm Hg and a diastolic pressure above 110 mmHg,
  • Cardiogenic shock defined by systolic blood pressure below 80 mm Hg
  • Contraindication to thrombolysis: History of AIC in the three months history of intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, arteriovenous malformation
  • Presumption of septic embolism or aortic dissection or pericardial effusion.
  • Recent biopsy or surgery within 3 months
  • Head injury less than 3 months
  • Known bleeding diathesis, taking anticoagulants with INR> 1.2
  • Hypoglycemia (blood glucose below 0.5 mmol / l)
  • Known renal, creatinine greater than 130 Mu / L
  • Recent Lumbar puncture <7days
  • Conditions prior psychiatric or neurological deficit does not allow objective analysis of disability
  • History of ischemic stroke or hemorrhagic
  • History of epilepsy and taking antiepileptic
  • Exclusion criteria Imaging
  • Structured hypodensity scanner compatible with recent ischemic stroke
  • Hematoma
  • Other lesions (tumor or inflammatory cerebral venous thrombosis)
  • The scanner Contraindications: allergy to iodine or major renal creatinine> 130μl or MRI referred to above
  • Women of childbearing age, pregnant or not recognized effective contraception
  • Patients in the measure of legal protection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01527240

Hospices Civils de Lyon
Lyon, France, 69002
Sponsors and Collaborators
Hospices Civils de Lyon
Principal Investigator: Norbert NIGHOGHOSSIAN Hospices Civils de Lyon
  More Information

Responsible Party: Hospices Civils de Lyon Identifier: NCT01527240     History of Changes
Other Study ID Numbers: 2008.544
Study First Received: January 31, 2012
Last Updated: May 15, 2014

Keywords provided by Hospices Civils de Lyon:
Volume of cerebral infarction

Additional relevant MeSH terms:
Cerebral Infarction
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pharmaceutical Solutions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on April 26, 2017